# 2382:  2026 Could Be a Defining Year for POLB 001 and Oral GLP-1

Page: https://stenobird.com/podcast/the-vox-markets-podcast-3914537/2382-2026-could-be-a-defining-year-for-polb-001-and-oral-glp-1
Text version: https://stenobird.com/podcast/the-vox-markets-podcast-3914537/2382-2026-could-be-a-defining-year-for-polb-001-and-oral-glp-1.md
Podcast: [The Vox Markets Podcast](https://stenobird.com/podcast/the-vox-markets-podcast-3914537)
Published: 2026-04-28T06:43:23+00:00
Episode link: https://audioboom.com/posts/8896364
Audio file: https://dts.podtrac.com/redirect.mp3/audioboom.com/posts/8896364.mp3?modified=1777358652&sid=5051662&source=rss
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/the-vox-markets-podcast-3914537/episodes/2382-2026-could-be-a-defining-year-for-polb-001-and-oral-glp-1
Duration seconds: 777

## Resource

Poolbeg Pharma CEO Jeremy Skillington discusses progress across POLB 001, including regulatory clearance, IP protection, US payer research and the path towards interim clinical data in cancer immunotherapy-induced CRS. He also updates investors on the company’s cash runway, partnering strategy and the potential commercial opportunity in oral GLP-1 therapies.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/the-vox-markets-podcast-3914537/episodes/2382-2026-could-be-a-defining-year-for-polb-001-and-oral-glp-1/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/the-vox-markets-podcast-3914537/2382-2026-could-be-a-defining-year-for-polb-001-and-oral-glp-1.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.